Table of Contents The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis TATA India PHARMA & Healthcare Fund - G
Scheme Objective
CAGR return of 9% since its launch. Return for 2020 was 64.4% , 2019 was 5.5% and 2018 was -2.6% . NAV as on 19 Apr 21 ₹15.7701 ↑ 0.09 (0.56 %) Net Assets (AUM) as on 28 Feb 2021 ₹413 Cr. Launch Date 28 Dec 2015 Category Equity - Sectoral Rating Type Open Ended Fund Risk High AMC Tata Asset Management Limited Alpha Ratio 3.33 Expense Ratio 2.61 % Sharpe Ratio 1.478 Information Ratio 0.67 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 Apr 21 Duration Returns 1 Month 11.9% 3 Month 3.8% 6 Month 16.3% 1 Year 48.1% 3 Year 21.8% 5 Year 10.4% 10 Year 15 Year Since launch 9% Historical Annual Returns
Year Returns 2020 64.4% 2019 5.5% 2018 -2.6% 2017 4.7% 2016 -14.7% 2015 2014 2013 2012 Growth of 10k Over Years
Date Value 31 Mar 16 ₹10,000 31 Mar 17 ₹9,719 31 Mar 18 ₹8,904 31 Mar 19 ₹9,694 31 Mar 20 ₹9,527 31 Mar 21 ₹15,709 
Asset Allocation
Asset Class Value Cash 2.42% Equity 97.58% 
Sector Allocation
Sector Value Health Care 97.58% 
Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | 500124Drug Manufacturers - Specialty & Generic 15% ₹60 Cr 135,500
↑ 27,900 Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMADrug Manufacturers - Specialty & Generic 10% ₹41 Cr 690,100 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 500087Drug Manufacturers - General 9% ₹36 Cr 460,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 8% ₹31 Cr 92,500 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMADrug Manufacturers - Specialty & Generic 7% ₹29 Cr 335,000
↑ 190,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 20 | ALKEMDrug Manufacturers - Specialty & Generic 6% ₹26 Cr 95,365
↑ 6,165 Ipca Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 16 | 524494Drug Manufacturers - Specialty & Generic 6% ₹23 Cr 125,426 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSPMedical Care Facilities 5% ₹22 Cr 70,500 Procter & Gamble Health Ltd Shs Dematerialised (Healthcare)
Equity, Since 31 Jul 18 | 500126Drug Manufacturers - Specialty & Generic 4% ₹17 Cr 26,000 Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 29 Feb 20 | NHMedical Care Facilities 4% ₹16 Cr 376,420
↓ -280,300
Talk to our investment specialistFund Managers
Name Since Tenure Rahul Singh 20 Apr 20 0.95 Yr. Meeta Shetty 20 Apr 20 0.95 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
Computer Age Management Services Ltd Address New No.10, Old No.178,,Kodambakkam High Road,,Opp. Hotel Palmgrove,,Nungambakkam FAX 91-44-28283610 Email enq_L@camsonline.com Administrator Companies
Company Address Tata Mutual Fund 1903, B-Wing, Parinee Crescenzo,,G-Block, Bandra Kurla Complex, Bandra East Mumbai 400051 Auditors
Company Address Deloitte Haskins & Sells 12, Dr. Annie Besant Road, Opp. Shiv Sagar Estate,,Worli M/s BSR & Co. KPMG House, Kamala Mills Compound,448 Senapati Bapat Marg,Lower Parel All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year TATA India Pharma & Healthcare Fund
Normal Dividend, Reinvestment ₹15.7701
↑ 0.09 16.3 % 48.13 % 21.78 % 10.36 % TATA India Pharma & Healthcare Fund
Normal Dividend, Payout ₹15.7701
↑ 0.09 16.3 % 48.13 % 21.78 % 10.36 % TATA India Pharma & Healthcare Fund
Growth ₹15.7701
↑ 0.09 16.3 % 48.13 % 21.78 % 10.36 % Data as on 19 Apr 21
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2021 Shepard Technologies Private Limited. All Rights Reserved